KYORIN Pharmaceutical (4569) · InitiativeAchieved
Fixing the Term of the Rocaltrol Distribution Agreement
First written in FY2019-Q3. 1 of 3 entries say "Restated". Latest entry: FY2020-Q1.
3entries
1years
0from disclosures
How it moved
Same theme, other companies
Business Impact from Termination or Unfavorable Amendment of Important ContractsA theme 95 companies write about · 101 as a headwind · 0 as a tailwind
The whole theme swung hardest in 2025: 6 of 28 companies on the "Worse" side.
2 other companies' latest entry also says "Achieved".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 95 companies compared. The sentences above are computed from all 95.Full recordFilings, disclosures and news, newest first
- FY2020-Q1AchievedAnnual report
「The contracts that ended during the first quarter of the current fiscal year due to expiration of their terms are as follows.」
The Rocaltrol sales agreement with Chugai Pharmaceutical ended upon expiration of its term on 31 May 2019. - FY2019RestatedAnnual report
「Rocaltrol Chugai Pharmaceutical Co., Ltd. 1986 Through 31 May 2019」
The company continues to disclose the condition that the term of the Rocaltrol sales agreement runs through 31 May 2019. - FY2019-Q3First statedAnnual report
「The contract term was changed from “automatically renewable” to “through 31 May 2019.”」
The distribution agreement for Rocaltrol with CHUGAI PHARMACEUTICAL CO.,LTD. was changed from automatic renewal to a fixed term ending 31 May 2019.